Seamless Early-Stage Clinical Drug Development (Phase 1 to 2a) for Novel therapeutic Agents for the Spectrum of Alzheimer's Disease (AD) and AD-related Dementias (ADRD) (UG3/UH3 Clinical Trial Required)
Federal funding opportunity PAR-25-226 from National Institutes of Health (Department of Health and Human Services).
Apply on Grants.gov →Application closes November 19, 2026
- Posted
- November 22, 2024
- Closes
- November 19, 2026
- Cost sharing
- No
- Instrument
- Cooperative Agreement
- Assistance listing
- 93.242
- Category
- Health
- Archives
- December 25, 2026
Program funding history
Awards made under Assistance Listing 93.242 across FY2024–FY2026, from public federal spending records.
- FY2024 obligated
- $1.8B
- FY2025 obligated
- $1.8B
- FY2026 (to date) obligated
- $945.1M
- Awards in window
- 7,145
Top recipients: Yale Univ, University of Pittsburgh - of the Commonwealth System of Higher Education, Icahn School of Medicine at Mount Sinai, University of California, Los Angeles, Washington University, the
Source: USAspending.gov · refreshed July 2026
Synopsis
Who can apply
- City or township governments
- Native American tribal organizations (other than Federally recognized tribal governments)
- For profit organizations other than small businesses
- Independent school districts
- Public housing authorities/Indian housing authorities
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- State governments
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Special district governments
- Public and State controlled institutions of higher education
- Small businesses
- Private institutions of higher education
- Native American tribal governments (Federally recognized)
- County governments
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
How to apply
Applications go through the official government listing. Grants Radar links you straight to the source.
Get grants like this every Tuesday — free
One email a week: the biggest new federal grants and what’s closing soon. Unsubscribe in one click.
Similar grants
- Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)
- Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Limited Competition: Small Grant Program for the NCATS Clinical and Translational Science Award (CTSA) Program (R03 Clinical Trial Optional)
- Dissemination and Implementation Research in Health (R01 Clinical Trial Optional)
- Dissemination and Implementation Research in Health (R21 Clinical Trial Optional)
Never miss a funding deadline again
Grants Radar sends AI-enriched alerts on federal grants and contracts matched to what you do. Founding seats are limited and locked for life.
Get funding alerts